PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghoneum, Alia, Said, Neveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679095/
https://www.ncbi.nlm.nih.gov/pubmed/31284467
http://dx.doi.org/10.3390/cancers11070949
_version_ 1783441258504519680
author Ghoneum, Alia
Said, Neveen
author_facet Ghoneum, Alia
Said, Neveen
author_sort Ghoneum, Alia
collection PubMed
description Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.
format Online
Article
Text
id pubmed-6679095
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66790952019-08-19 PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics Ghoneum, Alia Said, Neveen Cancers (Basel) Review Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells. MDPI 2019-07-05 /pmc/articles/PMC6679095/ /pubmed/31284467 http://dx.doi.org/10.3390/cancers11070949 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ghoneum, Alia
Said, Neveen
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title_full PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title_fullStr PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title_full_unstemmed PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title_short PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
title_sort pi3k-akt-mtor and nfκb pathways in ovarian cancer: implications for targeted therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679095/
https://www.ncbi.nlm.nih.gov/pubmed/31284467
http://dx.doi.org/10.3390/cancers11070949
work_keys_str_mv AT ghoneumalia pi3kaktmtorandnfkbpathwaysinovariancancerimplicationsfortargetedtherapeutics
AT saidneveen pi3kaktmtorandnfkbpathwaysinovariancancerimplicationsfortargetedtherapeutics

Ejemplares similares